Spots Global Cancer Trial Database for ras
Every month we try and update this database with for ras cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | NCT03597581 | Gastrointestina... Gastrointestina... Colorectal Canc... Colorectal Neop... Colorectal Carc... Gastric Cancer Gastric Neoplas... KRAS Mutation-R... CRC Colorectal Canc... | ompenaclid FOLFIRI Bevacizumab FOLFOX regimen | 18 Years - | Inspirna, Inc. | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| Phase I Trial of Defactinib and VS-6766. | NCT03875820 | NSCLC Low Grade Serou... Endometrioid Ca... Pancreatic Canc... | VS-6766 Defactinib | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | NCT06326411 | Oncology MEK Mutation RAF Gene Mutati... Ras (KRAS or NR... Melanoma NSCLC Glioma Solid Tumor, Ad... MAPK Pathway Ge... | NST-628 | 18 Years - | Nested Therapeutics, Inc | |
| Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy | NCT00001440 | Breast Neoplasm Neoplasm Metast... | Autologous T ce... Interleukin-2 | - | National Institutes of Health Clinical Center (CC) | |
| Open vs Robotic Assisted Partial Nephrectomy | NCT03849820 | Renal Cancer | Robotic-assiste... Open partial ne... | 18 Years - | Intuitive Surgical | |
| REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients | NCT05396807 | Metastatic Colo... | AI | 18 Years - | University of Rome Tor Vergata | |
| Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) | NCT00886353 | Pulmonary Disea... Cardiovascular ... Kidney Diseases Cancer Diseases | APN01 Placebo | 18 Years - | Apeiron Biologics | |
| Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer | NCT02103062 | Colorectal Neop... | ABI-007 | 18 Years - | Celgene | |
| Long-term Use of CCB and Breast Cancer Risk | NCT05972785 | Hypertension,Es... Breast Cancer | Calcium channel... Beta blocker Diuretic RAS Other AHT None AHT | 45 Years - | Curtin University | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy | NCT00001440 | Breast Neoplasm Neoplasm Metast... | Autologous T ce... Interleukin-2 | - | National Institutes of Health Clinical Center (CC) | |
| Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | NCT02906059 | Metastatic Colo... | AZD1775 Irinotecan | 18 Years - | NYU Langone Health | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
